The differences of clinical picture of macroprolactinomas and their response to medicamental therapy with dopamine agonists between men and women
https://doi.org/10.14341/probl201157311-16
Abstract
The data about sex-specific differences of clinical signs and symptoms of macroprolactinomas and their response to medicamental therapy with dopamine agonists between men and women are reported. The present study included 306 patients (the men to women ratio 1.4:1) presenting with macroprolactinomas. Large and giant neoplasms were shown to predominate in men regardless of their age accompanied by clinical symptoms associated with the so-called «mass effect» of the tumour. The occurrence of macroprolactinomas of different size depended on the age of the patients. The majority of the young women had tumours of large and intermediate size and exhibited clinical features of hyperprolactinemic hypogonadism while those aged above 40 years had large and giant tumours accompanied by the symptoms of their «mass effect». The medicamental treatment with cabergolin was equally efficacious in both men and women.
About the Authors
L I Astaf'evaB A Kadashev
I I Dedov
P L Kalinin
M A Kutin
V D Tenedieva
O F Tropinskaia
References
1. Corsello S.M., Ubertini G., Altomare M. et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 2003;58:5:662-670.
2. Shrivastava R.K., Arginteanu M.S., King W.A., Post K.D. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002;97:2:299-306.
3. Verhelst J., Abs R., Maiter D. et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:7:2518-2522.
4. Colao A., Sarno A.D., Cappabianca P. et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148:3:325–331.
5. Shimon I., Benbassat C., Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007;156:2:225-231.
6. Petrossians P., de Herder W., Kwekkeboom D. et al. Malignant prolactinoma discovered by D2 receptor imaging. J Clin Endocrinol Metab 2000;85:1:398-401.
7. Yang M.Y., Shen C.C., Ho W.L. Treatments of multi-invasive giant prolactinoma. J Clin Neurosci 2004;11:1:70-75.
8. Casanueva F.F., Molitch M.E., Schlechte J.A. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:2:265-273.
9. Дедов И.И., Мельниченко Г.А. Персистирующая галакторея-аменорея (этиология, патогенез, клиника, лечение). М 1985.
10. Дзеранова Л.К. Cиндром гиперпролактинемии у женщин и мужчин: клиника, диагностика, лечение: Автореф. дис. … д-ра мед. наук. М 2007.
11. Мельниченко Г.А. Гиперпролактинемический гипогонадизм (классификация, клиника, лечение): Автореф. дис. … д-ра мед. наук. М 1990.
12. Романцова Т.И. Особенности клинической симптоматики, диагностики и лечения синдрома гиперпролактинемии у женщин: Автореф. дис. … д-ра мед. наук. М 2001.
13. Ciccarelli A., Guerra E., De Rosa M. et al. PRL secreting adenomas in male patients. Pituitary 2005;8:1:39-42.
14. Melmed S. Update in pituitary disease. J Clin Endocrinol Metab 2008;93:2:331-338.
15. Di Sarno A., Landi M.L., Cappabianca P. et al. Resistance to cabergoline as compared to bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endocrinol Metab 2001;86:11:5256-5261.
16. Biller B.M., Molitch M.E., Vance M.L. et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:6:2338-2343.
17. Grossman A., Besser G.M. Prolactinomas. Br Med J 1985;290: 6463:182-184.
18. Cannavò S., Curtò L., Squadrito S. et al. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Inv 1999;22:5:354-359.
19. Colao A., Loche S., Cappa M. et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:8:2777-2780.
20. Delgrange E., Trouillas J., Maiter D. et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997;82:7:2102-2107.
Review
For citations:
Astaf'eva L.I., Kadashev B.A., Dedov I.I., Kalinin P.L., Kutin M.A., Tenedieva V.D., Tropinskaia O.F. The differences of clinical picture of macroprolactinomas and their response to medicamental therapy with dopamine agonists between men and women. Problems of Endocrinology. 2011;57(3):11-16. (In Russ.) https://doi.org/10.14341/probl201157311-16
Views:
331
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
